Skip to primary navigation
Skip to main content
Skip to primary navigation
Skip to main content
Toggle Search
Search
Choose which site to search.
Current site
All of UAMS
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller
Cancer Institute
UAMS Health
Jobs
Giving
Toggle Search
Toggle Primary Nav
About
From the Director
Our History
Leadership
Board of Advisors
Health Equity and Workforce Development
About Little Rock
Maps & Directions
Cancer Conversations Calendar
Cancer Institute Magazine
News
College of Medicine
Patient Care
Finding Your Way
Treatment
Prevention & Screenings
Patient Support
Clinical Trials
Research
Research Programs
Membership
Internal Funding
Shared Resources
Training and Education
Get Involved
Donate
Fundraising Events
Volunteer Services & Auxiliary
The Envoys
Contact
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
Recurring
Page 5
Tags:
Recurring
NCT04457596 – Alliance A011801, The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
NCT05812807 – Alliance A012103, OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
NCT03723928 – S1703 Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
NCT05306340 – A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s choice of Endocrine Therapy Exemestane Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04852887 – NRG-BR007: A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer
Previous
1
…
3
4
5